TMPRSS2 and prostate cancer: In the present study, we analyzed the molecular composition and distribution of genomic TMPRSS2-ERG fusion sites from 24 newly sequenced cases together with 34 previously reported patients with prostate cancer to evaluate the suitability of this genomic fusion sequence as a noninvasive tumor marker for patients with prostate cancer.